Ashburton Jersey Ltd Invests $8.77 Million in Johnson & Johnson (NYSE:JNJ)

Ashburton Jersey Ltd bought a new position in shares of Johnson & Johnson (NYSE:JNJ) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 59,898 shares of the company’s stock, valued at approximately $8,771,000. Johnson & Johnson makes up about 3.7% of Ashburton Jersey Ltd’s holdings, making the stock its 11th largest holding.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Clifford Capital Partners LLC raised its holdings in Johnson & Johnson by 53.5% during the 2nd quarter. Clifford Capital Partners LLC now owns 101,809 shares of the company’s stock worth $14,880,000 after buying an additional 35,481 shares during the period. University of Texas Texas AM Investment Management Co. raised its holdings in shares of Johnson & Johnson by 16.3% during the second quarter. University of Texas Texas AM Investment Management Co. now owns 21,979 shares of the company’s stock valued at $3,212,000 after acquiring an additional 3,087 shares during the period. Verity & Verity LLC lifted its position in shares of Johnson & Johnson by 8.6% in the 2nd quarter. Verity & Verity LLC now owns 89,227 shares of the company’s stock valued at $13,041,000 after acquiring an additional 7,032 shares in the last quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group boosted its stake in Johnson & Johnson by 10.2% in the 2nd quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group now owns 8,771 shares of the company’s stock worth $1,282,000 after purchasing an additional 814 shares during the period. Finally, Summit Wealth Partners LLC grew its position in Johnson & Johnson by 0.6% during the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company’s stock worth $1,463,000 after purchasing an additional 61 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. TD Cowen reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 20th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Stock Performance

JNJ stock opened at $161.17 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $387.88 billion, a price-to-earnings ratio of 10.05, a P/E/G ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The firm has a 50 day moving average of $162.60 and a two-hundred day moving average of $154.26.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.80 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.08%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.